Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Malaria, which is caused by infection of red blood cells with Plasmodium parasites, can be
fatal in non-immune individuals if left untreated. The recent approval of the pre-erythrocytic …

Diverse compounds target the Plasmodium falciparum Na+ pump PfATP4, with cipargamin
and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin …

The Pd–Cu catalysed Sonogashira coupling of terminal alkynes and aryl halides is a
cornerstone synthetic strategy for C–C bond formation. Homogeneous organometallic …

Plasmodium falciparum artemisinin (ART) resistance is driven by mutations in kelch-like
protein 13 (PfK13). Quiescence, a key aspect of resistance, may also be regulated by a yet …

The Plasmodium falciparum proteasome constitutes a promising antimalarial target, with
multiple chemotypes potently and selectively inhibiting parasite proliferation and synergizing …

Although malaria remains a big burden to many countries that it threatens their socio-
economic stability, particularly in the countries where malaria is endemic, there have been …

Given the current global climate and health challenges, sustainability and cost-effectiveness
are becoming unavoidable factors that must be considered in the development of new …

Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria
elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl …

The development of new combinations of antimalarial drugs is urgently needed to prevent
the spread of parasites resistant to drugs in clinical use and contribute to the control and …